Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Alzheimer Disease and Associated Disorders

• Publication date

  1998-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00002093-199812000-00010PMID 9876958
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper
• The Safety and Tolerance of Xanomeline Tartrate in Patients with Alzheimer's Disease

  1995cited by this paper
• Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

  1994cited by this paper
• Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

  1994cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .

  1992cited by this paper
• Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group.

  1992cited by this paper
• Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

  1991cited by this paper
• Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease.

  1989cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Alzheimer's disease: a disorder of cortical cholinergic innervation.

  1983cited by this paper
• Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

  1982cited by this paper
• Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities.

  1982cited by this paper
• Simple and choice reaction time in dementia: clinical implications.

  1981cited by this paper
• Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease.

  1980cited by this paper
• Pathological verification of ischemic score in differentiation of dementias

  1980cited by this paper
• Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

  1978cited by this paper
• Reaction Time as a Diagnostic Measure in Senility *

  1976cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper

• The effect of biperiden on episodic memory: Testing the serial position effect.

  2025cites this paper
• Efficacy of xanomeline and xanomeline trospium in the treatment of cognitive impairment: A systematic review of preclinical and clinical trials.

  2025cites this paper
• Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis.

  2025cites this paper
• The Prosperity and Adversity of M4 Muscarinic Acetylcholine Receptor Activators in the Treatment of Neuropsychiatric Disorders.

  2025cites this paper
• Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment

  2024cites this paper
• The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.

  2024cites this paper
• The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia

  2024cites this paper
• Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.

  2024cites this paper
• Discovery of 2-Methyl-5-(1H-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M4 mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders.

  2024cites this paper
• Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.

  2024cites this paper
• M1/M4-Preferring Muscarinic Cholinergic Receptor Agonist Xanomeline Reverses Wake and Arousal Deficits in Nonpathologically Aged Mice

  2023cites this paper
• A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease

  2022cites this paper
• The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer’s disease

  2022cites this paper
• Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review

  2022cites this paper
• Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

  2021cites this paper
• Critical Role of Hippocampal Muscarinic Acetylcholine Receptors on Memory Reconsolidation in mice.

  2020cites this paper
• Dangerous Liaisons: Tau Interaction with Muscarinic Receptors

  2020cites this paper
• Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.

  2019cites this paper
• In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography

  2018cites this paper
• Game-Based Assessment of Cognitive Status in Clinical and Non-Clinical Samples

  2018cites this paper
• Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia

  2017cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease.

  2016cites this paper
• Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy.

  2016cites this paper
• The muscarinic system, cognition and schizophrenia.

  2015cites this paper
• Computerized Cognitive Testing for Older Adults

  2015influential citation
• Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

  2015cites this paper
• A mobile application for cognitive screening of dementia

  2015cites this paper
• PACAP-Based Therapy for Alzheimer ’ s Disease

  2014cites this paper
• Envisioning PACAP-Based Therapy for Alzheimer's Disease.

  2014cites this paper
• Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

  2013cites this paper
• Effect of Cholinergic Signaling on Neuronal Cell Bioenergetics

  2013cites this paper
• Muscarinic mechanisms in psychotic disorders.

  2012cites this paper
• Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.

  2012cites this paper
• Muscarinic receptor pharmacology and circuitry for the modulation of cognition.

  2012cites this paper
• Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.

  2010cites this paper
• Topiramate dose effects on cognition

  2010cites this paper
• AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

  2010cites this paper
• Cholinergics/Anticholinergics/Muscarinics/Nicotinics

  2010cites this paper
• Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.

  2010cites this paper
• 1.2 Cholinergic Mechanisms in Schizophrenia

  2009cites this paper
• A new Brief computerized cognitive screening battery (CompCogs) for early diagnosis of Alzheimer’s disease

  2008cites this paper
• Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme

  2008cites this paper
• Cholinergic components of frontal lobe function and dysfunction.

  2008cites this paper
• Status of computerized cognitive testing in aging: A systematic review

  2008cites this paper
• A neuropsychological test battery for use in Alzheimer disease clinical trials.

  2007cites this paper
• Anticholinergic medications and cognition in older adults

  2007cites this paper
• Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

  2006cites this paper
• Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

  2006cites this paper
• A model of anticholinergic activity of atypical antipsychotic medications.

  2006cites this paper
• Clinical evaluation as a biomarker for Alzheimer's disease

  2006cites this paper
• 進行性核上性麻痺の治療up-to-date2005

  2005cites this paper
• Cholinergic systems in progressive supranuclear palsy.

  2004cites this paper
• Drugs that target muscarinic cholinergic receptors

  2004cites this paper
• The evaluation of cognitive function in the dementias: methodological and regulatory considerations

  2003cites this paper
• [Treatment of Alzheimer's disease].

  2002cites this paper
• Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies.

  2002cites this paper
• Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit

  2002cites this paper
• Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor.

  2002cites this paper
• Pharmacokinetic‐Pharmacodynamic Modeling of Rivastigmine, a Cholinesterase Inhibitor, in Patients with Alzheimer's Disease

  2001cites this paper
• Galantamine: Additional Benefits to Patients with Alzheimer’s Disease

  2000cites this paper
• Mild Cognitive Impairment: Emerging Therapeutics

  2000cites this paper
• Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease

  2000cites this paper
• Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Functional and Quality of Life Scales

  2000cites this paper
• Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease

  1999cites this paper